Literature DB >> 17301827

Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis.

T H Karlsen1, K M Boberg, M Vatn, A Bergquist, J Hampe, E Schrumpf, E Thorsby, S Schreiber, B A Lie.   

Abstract

Approximately 80% of patients with primary sclerosing cholangitis (PSC) of Northern European origin have inflammatory bowel disease (IBD), the majority ulcerative colitis (UC). An inherent problem in interpreting positive findings in genetic association studies of PSC is thus to distinguish between factors associated with hepatobiliary versus intestinal pathology. We aimed to clarify to what extent human leukocyte antigen (HLA) class II associations in UC patients with and without PSC differ. High-resolution DRB1 and DQB1 typing was performed in 365 Scandinavian PSC patients, an independent cohort of 330 Norwegian UC patients and 368 healthy controls. HLA associations found in PSC were mostly distinct from those seen in UC, and no significant differences were noted between PSC patients with concurrent UC and PSC patients without IBD. This suggests different HLA associated genetic susceptibility to PSC and UC, and supports notions that UC in PSC may represent a distinct UC phenotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301827     DOI: 10.1038/sj.gene.6364377

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  17 in total

1.  Sclerosing cholangitis in baboons (Papio spp) resembling primary sclerosing cholangitis of humans.

Authors:  A M Arenas-Gamboa; J J Bearss; G B Hubbard; B F Porter; M A Owston; E J Dick
Journal:  Vet Pathol       Date:  2011-09-20       Impact factor: 2.221

Review 2.  Genetic epidemiology of primary sclerosing cholangitis.

Authors:  Tom-H Karlsen; Erik Schrumpf; Kirsten-Muri Boberg
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

3.  Development of a high-resolution NGS-based HLA-typing and analysis pipeline.

Authors:  Michael Wittig; Jarl A Anmarkrud; Jan C Kässens; Simon Koch; Michael Forster; Eva Ellinghaus; Johannes R Hov; Sascha Sauer; Manfred Schimmler; Malte Ziemann; Siegfried Görg; Frank Jacob; Tom H Karlsen; Andre Franke
Journal:  Nucleic Acids Res       Date:  2015-03-09       Impact factor: 16.971

4.  HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry.

Authors:  E K K Henriksen; M K Viken; M Wittig; K Holm; T Folseraas; S Mucha; E Melum; J R Hov; K N Lazaridis; B D Juran; O Chazouillères; M Färkkilä; D N Gotthardt; P Invernizzi; M Carbone; G M Hirschfield; S M Rushbrook; E Goode; C Y Ponsioen; R K Weersma; B Eksteen; K K Yimam; S C Gordon; D Goldberg; L Yu; C L Bowlus; A Franke; B A Lie; T H Karlsen
Journal:  HLA       Date:  2017-07-11       Impact factor: 4.513

5.  Cutting edge issues in primary sclerosing cholangitis.

Authors:  Christopher L Bowlus
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

Review 6.  Update on inflammatory bowel disease in patients with primary sclerosing cholangitis.

Authors:  Christos Tsaitas; Anysia Semertzidou; Emmanouil Sinakos
Journal:  World J Hepatol       Date:  2014-04-27

Review 7.  Genetics of primary sclerosing cholangitis and pathophysiological implications.

Authors:  Xiaojun Jiang; Tom H Karlsen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-03-15       Impact factor: 46.802

8.  Clinical profile and outcome of primary sclerosing cholangitis: A single-centre experience from western India.

Authors:  Pratik Tibdewal; Pratin Bhatt; Abhinav Jain; Deepak Gupta; Shobna Bhatia; Akash Shukla
Journal:  Indian J Gastroenterol       Date:  2019-09-12

Review 9.  Primary Sclerosing Cholangitis: Multiple Phenotypes, Multiple Approaches.

Authors:  Souvik Sarkar; Christopher L Bowlus
Journal:  Clin Liver Dis       Date:  2015-10-06       Impact factor: 6.126

Review 10.  The immunobiology of primary sclerosing cholangitis.

Authors:  Jonathan H Aron; Christopher L Bowlus
Journal:  Semin Immunopathol       Date:  2009-05-26       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.